Nakamura Shingo, Ando Naoko, Ishihara Masayuki, Sato Masahiro
Division of Biomedical Engineering, National Defense Medical College Research Institute, Saitama 359-8513, Japan.
Section of Gene Expression Regulation, Frontier Science Research Center, Kagoshima University, Kagoshima 890-8544, Japan.
Nanomaterials (Basel). 2020 Aug 12;10(8):1584. doi: 10.3390/nano10081584.
We previously reported that heparin/protamine particles (LHPPs) produced as nanoparticles through simple mixing of raw materials exhibit sustained protein release and can be retained in cells. In the present study, we modified LHPPs without employing any organic synthetic approach. The resulting LHPPs were re-named as improved LHPPs (-LHPPs) and have the ability to retain cell-penetrating peptides (GRKKRRQRRRPPQ) based on electrostatic interactions. We examined whether -LHPPs can introduce exogenous proteins (i.e., lacZ protein encoding bacterial β-galactosidase) into cultured cells in vitro, or into murine hepatocytes in vivo through intravenous injection to anesthetized mice. We found an accumulation of the transferred protein in both in vitro cultured cells and in vivo hepatocytes. To the best of our knowledge, reports of successful in vivo delivery to hepatocytes are rare. The -LHPP-based protein delivery technique will be useful for in vivo functional genetic modification of mouse hepatocytes using Cas9 protein-mediated genome editing targeting specific genes, leading to the creation of hepatic disease animal models for research that aims to treat liver diseases.
我们之前报道过,通过简单混合原材料制备成纳米颗粒的肝素/鱼精蛋白颗粒(LHPPs)具有持续的蛋白质释放能力,并且能够滞留在细胞中。在本研究中,我们未采用任何有机合成方法对LHPPs进行了修饰。所得的LHPPs重新命名为改良型LHPPs(-LHPPs),其基于静电相互作用具有保留细胞穿透肽(GRKKRRQRRRPPQ)的能力。我们研究了-LHPPs是否能够在体外将外源蛋白(即编码细菌β-半乳糖苷酶的lacZ蛋白)导入培养细胞,或者通过静脉注射到麻醉小鼠体内,将其导入小鼠肝细胞。我们发现在体外培养细胞和体内肝细胞中均有转移蛋白的积累。据我们所知,成功将蛋白体内递送至肝细胞的报道很少见。基于-LHPPs的蛋白质递送技术将有助于利用Cas9蛋白介导的针对特定基因的基因组编辑对小鼠肝细胞进行体内功能基因修饰,从而创建用于治疗肝脏疾病研究的肝病动物模型。